These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15176173)

  • 1. Health technology assessment in England and Wales.
    Stevens A; Milne R
    Int J Technol Assess Health Care; 2004; 20(1):11-24. PubMed ID: 15176173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
    Taylor R
    Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health technology assessment in England: assessment and appraisal.
    Walley T
    Med J Aust; 2007 Sep; 187(5):283-5. PubMed ID: 17767433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health technology assessment for the NHS in England and Wales.
    Woods K
    Int J Technol Assess Health Care; 2002; 18(2):161-5. PubMed ID: 12053415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
    Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
    Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HTA'd in the USA: A Comparison of ICER in the United States with NICE in England and Wales.
    Thokala P; Carlson JJ; Drummond M
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1162-1170. PubMed ID: 32857653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
    Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
    BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Views of Directors of Public Health about NICE Appraisal Guidance: results of a postal survey. National Institute for Clinical Excellence.
    Davies E; Littlejohns P
    J Public Health Med; 2002 Dec; 24(4):319-25. PubMed ID: 12546211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health technology assessment and evidence-based policy making: Queensland Department of Health experience.
    Ju H; Hewson K
    Int J Technol Assess Health Care; 2014 Dec; 30(6):595-600. PubMed ID: 25816825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients' views of explicit rationing: what are the implications for health service decision-making?
    Devlin N; Appleby J; Parkin D
    J Health Serv Res Policy; 2003 Jul; 8(3):183-6. PubMed ID: 12869346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does the use of health technology assessment have an impact on the utilisation of health care resources? Evidence from two European countries.
    Corbacho B; Drummond M; Santos R; Jones E; Borràs JM; Mestre-Ferrandiz J; Espín J; Henry N; Prat A
    Eur J Health Econ; 2020 Jun; 21(4):621-634. PubMed ID: 32026155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of the impact of the NHS Health Technology Assessment Programme.
    Hanney S; Buxton M; Green C; Coulson D; Raftery J
    Health Technol Assess; 2007 Dec; 11(53):iii-iv, ix-xi, 1-180. PubMed ID: 18031652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradigms in operation: explaining pharmaceutical benefit assessment outcomes in England and Germany.
    Kieslich K
    Health Econ Policy Law; 2020 Jul; 15(3):370-385. PubMed ID: 30975237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STAKEHOLDERS' PERCEPTIONS OF HEALTH TECHNOLOGY ASSESSMENT IN TURKEY.
    Ozturk K; Karadayı B; Şener O
    Int J Technol Assess Health Care; 2018 Jan; 34(1):97-104. PubMed ID: 29151380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing Health Technology Assessment to address health care system needs.
    Velasco Garrido M; Gerhardus A; Røttingen JA; Busse R
    Health Policy; 2010 Mar; 94(3):196-202. PubMed ID: 19889471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.